Utility and interpretation of multiple breath washout in children with cystic fibrosis.
Uložené v:
| Názov: | Utility and interpretation of multiple breath washout in children with cystic fibrosis. |
|---|---|
| Autori: | Dobra R; National Heart and Lung Institute, Imperial College London, London, UK r.dobra@imperial.ac.uk.; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK., Short C; National Heart and Lung Institute, Imperial College London, London, UK.; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK., Wong K; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK., Saunders C; National Heart and Lung Institute, Imperial College London, London, UK.; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK., Abkir M; National Heart and Lung Institute, Imperial College London, London, UK.; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK., Irving S; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK., Davies JC; National Heart and Lung Institute, Imperial College London, London, UK.; Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. |
| Zdroj: | Archives of disease in childhood. Education and practice edition [Arch Dis Child Educ Pract Ed] 2025 Sep 18; Vol. 110 (5), pp. 214-217. Date of Electronic Publication: 2025 Sep 18. |
| Spôsob vydávania: | Journal Article |
| Jazyk: | English |
| Informácie o časopise: | Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101220684 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-0593 (Electronic) Linking ISSN: 17430585 NLM ISO Abbreviation: Arch Dis Child Educ Pract Ed Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BMJ Pub. Group, c2004- |
| Výrazy zo slovníka MeSH: | Cystic Fibrosis*/physiopathology , Cystic Fibrosis*/diagnosis , Respiratory Function Tests*/methods, Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Male ; Breath Tests/methods |
| Abstrakt: | Competing Interests: Competing interests: RD has accepted honoraria from Vertex Pharmaceuticals and Chiesi and has been awarded grants from the Cystic Fibrosis Trust. JCD has undertaken clinical trial leadership and/ or Advisory Board and speaking roles for Vertex Pharmaceuticals, Boehringer-Ingelheim, Eloxx, Algipharma, Abbvie, Arcturus, Enterprise Therapeutics, Recode, LifeArc, Genentech, and Tavanta. She has been awarded research grants from the UK Cystic Fibrosis Trust, Cystic Fibrosis Foundation, Cystic Fibrosis Ireland, EPSRC, NIHR and LifeArc. Transformative changes in the health of children with cystic fibrosis (CF) mean that more sensitive outcome measures are needed to monitor paediatric CF lung disease. Multiple breath washout (MBW) and its primary readout lung clearance index are gaining increasing traction as an endpoint for clinical trials in the CF space and show promise as a clinical investigation. In this article, we use four clinically based questions to explore what MBW can and cannot (yet) do and highlight some of its strengths and weaknesses as an investigation. We end by discussing how we can increase the utility of MBW as an investigation in children with CF. (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.) |
| Contributed Indexing: | Keywords: Cystic Fibrosis; Physiology; Respiratory Medicine |
| Entry Date(s): | Date Created: 20250113 Date Completed: 20250918 Latest Revision: 20250922 |
| Update Code: | 20250922 |
| DOI: | 10.1136/archdischild-2024-328203 |
| PMID: | 39805677 |
| Databáza: | MEDLINE |
Nájsť tento článok vo Web of Science | Abstrakt: | Competing Interests: Competing interests: RD has accepted honoraria from Vertex Pharmaceuticals and Chiesi and has been awarded grants from the Cystic Fibrosis Trust. JCD has undertaken clinical trial leadership and/ or Advisory Board and speaking roles for Vertex Pharmaceuticals, Boehringer-Ingelheim, Eloxx, Algipharma, Abbvie, Arcturus, Enterprise Therapeutics, Recode, LifeArc, Genentech, and Tavanta. She has been awarded research grants from the UK Cystic Fibrosis Trust, Cystic Fibrosis Foundation, Cystic Fibrosis Ireland, EPSRC, NIHR and LifeArc.<br />Transformative changes in the health of children with cystic fibrosis (CF) mean that more sensitive outcome measures are needed to monitor paediatric CF lung disease. Multiple breath washout (MBW) and its primary readout lung clearance index are gaining increasing traction as an endpoint for clinical trials in the CF space and show promise as a clinical investigation. In this article, we use four clinically based questions to explore what MBW can and cannot (yet) do and highlight some of its strengths and weaknesses as an investigation. We end by discussing how we can increase the utility of MBW as an investigation in children with CF.<br /> (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.) |
|---|---|
| ISSN: | 1743-0593 |
| DOI: | 10.1136/archdischild-2024-328203 |